Objective: This study was carried out to determine the prevalence of Glucose-6-phosphate dehydrogenase (G6PD) defi ciency among population of selected malaria endemic districts in central and eastern terai of Nepal.
INTRODUCTION
Glucose-6-phosphaste dehydrogenase (G6PD) is an important enzyme in cellular metabolism in the fi rst and rate-limiting step of pentose-phosphate pathway.
Among the functions of this pathway is the protection of cells from oxidative stress, through its role in conversion of NADP to NADPH, thereby replenishing the levels of reduced glutathione. As erythrocytes lack other detoxifying enzymes, people with G6PD defi ciency are susceptible to oxidative stress in their red blood cells (Cappellini and Fiorelli 2008) . The G6PD gene is located on the X chromosome, and as a result defi ciency shows X-linked inheritance, whereby a higher proportion of males suffer from the defi ciency.
Malaria in humans is predominantly caused by two
Plasmodium species, Plasmodium falciparum and Plasmodium vivax and is estimated to be spread over more than 90 countries, putting nearly 3.3 billion people at risk of disease (Guerra et al. 2010 , WHO 2012 . The prevalence of G6PD across countries was found to have a good correlation with those where, historically, malaria transmission has occurred (Howes et al. 2012) . The explanation for this association has been that G6PD is associated with protection against P. falciparum (Mockenhaupt et al. 2003; Clark et al. 2009 ) and P. vivax infections (Leslie et al. 2010; Santana et al. 2013) . The mechanism confer ring resistance in G6PD subjects may be related to an impaired antioxidant defence in ring-stage parasitized red cells, which could lead to membrane damage, triggering increased removal of infected cells by phagocytosis before parasite maturation to the trophozoite and schizont stages (Ruwende et al. 1995) .
G6PD is also thought to be a pro tection factor against severe manifestations of malaria, al though studies regarding which individuals, hemizygous males or heterozygous females, may be protected present TUJM VOL. 4, NO. 1, 2017 discrepancies (Ruwende et al. 1995; Guindo et al. 2007 ). G6PD defi ciency is common in malaria endemic regions and is estimated to affect more than 400 million people worldwide. It is a genetic defect, which is one of the most prevalent polymorphisms and enzymopathies in humans, particularly in males.
This genetic defect was discovered in 1956 when some patients developed haemolyticanaemia after the dose of the anti-malarial drug primaquine. G6PD-defi cient erythrocytes are more susceptible to destruction by oxidative stress than normal erythrocytes due to the lower NADPH levels. Individuals with this genetic defect may exhibit non-immune haemolyticanaemia in response to a number of stimuli, most commonly infections or exposure to certain medications or chemicals. Fortunately, the large majority of G6PD defi cient subjects have no clinical manifestations and the condition remains asymptomatic until they are exposed to a hemolytic trigger.
The geographical distribution of malaria is remarkably similar to the world distribution of defi cient G6PD variants. It is postulated that the high frequency of G6PD defi ciency has arisen because G6PD defi cient variants confer some protection or resistance against malaria caused by Plasmodium falciparum and Plasmodium vivax.
In Southeast Asia, a large number of G6PD defi cient variants have been reported from various populations.
In Nepal, previous studies have shown that G6PD defi ciency in Tharu ethnic inhabitants of Chitwan districts (WHO 2013) . With the development after 1960's and movement of population the scenario is likely to be changed. In a study done by Suzuki et al. 2007 it was observed that the group that has lived for many decades in malaria endemic lowland area, the Danuwar, was found to have a high prevalence of alpha-thalassaemia (79.4%) and low prevalence of haemoglobin E and G6PD defi ciency. Much lower prevalence of alpha-thalassaemia were observed in the Newar (20.5%), Parbate (16.5%) and Tamang (8.8%), who, until the 1950s, all spent their hot-season nights in malaria-free areas at higher altitude.
Glucose-6-phosphate dehydrogenase defi ciency poses a signifi cant impediment to primaquine use for the elimination of liver stage infection with Plasmodium vivax and for gametocyte clearance, because of the risk of life-threatening haemolytic anaemia that can occur in G6PD defi cient patients. Although a range of methods for screening G6PD defi ciency have been described, almost all require skilled personnel, expensive laboratory equipment, freshly collected blood, and is time consuming; factors that render them unsuitable for mass-screening purposes. So commercially available RDT/ICT card tests: BinaxNow-G6PD and CareStart G6PD were used for determination of G6PD defi ciency for mass screening purposes (Tinley et al. 2010 , Kim et al. 2011 , vonFricken et al. 2014 . This cross sectional study was designed to detect the prevalence of G6PD defi ciency in indigenous peoples communities of Jhapa, Morang and Dhanusha districts. Evidence from such a study would be important for taking policy decision on the use of G6PD RDTs, and use/abstinence of Primaquine in specifi c population/age groups, as a radical treatment of malaria.
MATERIALS AND METHODS
Study design, study site and study population: The study was designed as a descriptive cross-sectional study. The study was conducted during April to June years were excluded from the study.
Sample collection and testing:
The blood samples from the voluteers were taken by squeezing fi ngertip and piercing with lancet. The qualitative G6PD testing were performed using BinaxNow G6PD and CareStart TM G6PD test kits. All the tests were done at the collection site, maintaining aseptic condtion and universal precations.
Testing of G6PD defi ciency by BinaxNow kit:
BinaxNow G6PD test kits were used for follwoing manufacturer's instructions. Briefl y, the device from the pouch was removed prior to use, brought to room temperature, and was recorded on the front of the device. The test was performed at the temperature between 18°C to 25°C. 70μl of reagent-A and 10μl of blood from the volunteer was mixed in the sample preparation vial with the help of sterile micropipette mixed 3 times with push and pull by micropipette. Fifty microliter of mixed blood sample was added slowly to the middle of white pad of the test. The adhesive stripe was removed and the device was closed. The result was noted after 7 minutes. A distinct color change to black/brown on the top half of the reaction pad in visible reading window was considered normal while if there was no color change in the top half of the reaction pad in 7 minutes the samples were considered as G6PD defi cient (Tinley et al. 2010 ).
Testing of G6PD defi ciency by CareStart TM kit method:
CareStart TM G6PD testing was performed following manufacturers' instruction. Briefl y, the area of fi ngertip to be pierced was cleaned with alcohol pad and fi ngertip was squeezed and pierced using sterile lancet.
Blood sample (2μl) was collected using sample pipette provided by the kit. Whole blood (2μl) was applied to the sample well in the test kit. Immediately after application of blood 2 drop (100 μl) of assay buffer was added to buffer well. The result was noted 10 minutes.
Samples with normal G6PD produced a distinct purple color in the result window, ehile no color change was observed with G6PD defi cient samples (Kim et al. 2011) .
RESULTS
During the study period, a total of 670 whole blood samples were tested by rapid screening test for G6PD
(Glucose-6-phosphate dehydrogenase) defi ciency in human blood by using Carestart TM G6PD kit and BinaxNow G6PD kit.
Comparison of G6PD diagnostic test kits
Out of 670 blood samples tested for G6PD defi ciency, 6.1% (41) were found to be G6PD defi cient in BinaxNow while 6.3% (42) Sex wise distribution of G6PD defi cient cases Among 42 G6PD defi cient cases 21(7.3%) were male and 21(5.4%) were female. There is no signifi cant association of G6PD defi ciency with sex (p=0.529) ( Table 2) . Distribution of G6PD defi cient cases in different ethnic groups G6PD defi ciency was evaluated in the ethnic group population of the above 3 districts. The highest percentage of defi cient cases were from Rajbanshi followed by Santhal, Rishidev and Tharu community among the three districts (Table 3) . (Ghimire et al. 2017 ).
Glucose-6-phosphate dehydrogenase (G6PD) is a ubiquitously expressed enzyme that has a housekeeping role in all cells, and is particularly critical to the integrity and functioning of red blood cells (RBCs). G6PD is an important enzyme in cellular metabolism and ratelimiting step of pentose-phosphate pathway. Among the functions of this pathway is the protection of cells from oxidative stress, through its role in conversion of NADP to NADPH, thereby replenishing the levels of reduced glutathione. As erythrocytes lack other detoxifying enzymes, people with G6PD defi ciency are susceptible to oxidative stress in their red blood cells (Cappellini and Fiorelli 2008) .
Primaquine is the only -antimalarial drug recommended by WHO for the radical cure of malaria. However, a major barrier to widescale adoption of both of these drugs is toxicity in people with G6PD defi ciency. While all people exposed to primaquine experience some drop in haemoglobin concentrations (Kellermeyer et al. 1962) , people with G6PD defi ciency are more likely to experience severe haemolysis, leading to severe haemolyticanaemia and, potentially, death.
The blood samples from the volunteer participants inhabiting the malaria endemic districts and consenting to participate in the study through the written consent were tested on the spot by using G6PD kits BinaxNow G6PD and CareStart TM G6PD kits. Out of 670 volunteer tested for G6PDd, 6.1% were detected as G6PD defi cient were detected by BinaxNow G6PD RDT and 6.3% by CareStart TM G6PD RDT. Although the detection of G6PDd by BinaxNow is slighly more than that by CareStart TM RDT the difference is not statistically signifi cant. Low prevalence of G6PD defi ciency was reported from Latin America (Monteiro et al. 2014 ) whereas average prevalence of G6PD defi ciency (2.1%) with apparent differences between ethnic groups and geographical regions was reported from Tanjania (Rebholtz et al. 2006 ). The variation is due to the geographical variation in sampling area, and ethnic groups of the people.
Compared to BinaxNow G6PD kit method sensitivity and specifi city of the Carestart TM is 73.17% and 98.09%. Positive predictive value of test is 71.42% and negative predictive value is 98.24%. However, different sensitivity (86%) and nearly same specifi city (98%) value were reported from a study done in UK (Tinley et al. 2010) . The result was also inconsistence to the similar study in cape coast Ghana (Daniel et al. 2010) . The factors responsible for the poor performance of the District wise distribution of G6PD defi cient cases Highest percentage of defi cient cases was noted from Jhapa district followed by Morang and Dhanusha respectively.There was signifi cant association between G6PD defi ciency and region (p=0.010). kits might be the storage temperature, the temperature at which the test is performed, the ethnic community of Ghana and Nepal and also the geographical distribution of Nepal.
Among the G6PD defi cient cases, male and female ratio was 1:1 and there was no signifi cant relationship between gender and occurrence of G6PD defi ciency (p=0.529). This fi nding is different than other studies in which number of G6PD defi cient cases were more in male (Nimol et al. 2010; Julien et al. 2011) . The reason for this is still unknown and requires further molecualr level investigation with more countrywide sample representation.
Looking at G6PDd distribution in different indigenous groups staying in the study area highest number of confi rmed defi cient cases were from Rajbanshi (11.7%) followed by Santhal (10.2%), Rishidev (6.6%) and Tharu (5.3%) in the three study districts. Higher prevalence of G6PDd was found in Jhapa (9.8%) and Morang districts (5; 8%) this result is concordance with previous studies of Hongkong, Combodia, UK and in Ghana (Nimol et al. 2010; Daniel et al. 2012) . The parasite causing diseases like malaria cannot survive well in the G6PD defi cient cells. One of the schools of thought is "The ethnic community or inhabitants of malaria endemic areas are being exposed to such parasites for centuries and hence defi ciency is developed and inherited for generations for providing protection against deadly P. falciparum malaria. In context of Nepal, Tharu, Chaudhary, Rajbanshi, Santhal and Rishidev communities are majority inhabitants of malaria endemic districts since centuries, are still thought to be immune for deadly falciparum malaria. The G6PD defi ciency on such community might have developed in the long run to maintain their immunity against P. falciparum malaria, The scientifi c basis of which requires further studies at molecualr level. This study simply tried to fi nd out the qualitative information on G6PDd in different indigenous population taking in to consideration for introducing mandatory G6PDd testing in confi rmed P. vivax cases, for effective implementation of radical treatment with Primaquine following Chloroquine as per national malaria treatment protocol.
Malaria elimination will be possible only with serious national, regional and international efforts addressing asymptomatic infection and persis tent P. vivax infection. Currently available drugs that can radically cure P. vivax malaria and are able to re duce transmission of malaria parasites are those in the 8-aminoquinoline family, such as PQ. Tafenoquine, which is also an 8-aminoquinoline, is currently being assessed as a single-dose radical cure therapy, once it is approved for marketting following successful complition of clinical trials and market authorization. Un fortunately, individuals carrying the G6PDd are at risk to develop severe haemolysis if exposed to these drugs, implying that radical cure regimens will re quire broader testing for G6PD defi ciency. 
CONCLUSION

